re: Ann: EU Marketing Authorisation Applicati... I understand that Pulmozyme was rejected first time around by EMA.
Does anyone know the reasons behind this and also why it was approved on appeal?
On the safety front, mannitol has a good solid profile given that the compound has been used extensively for many treatments including head trauma etc.
- Forums
- ASX - By Stock
- SNT
- Ann: EU Marketing Authorisation Application Revie
Ann: EU Marketing Authorisation Application Revie, page-7
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.2¢ |
Change
0.002(5.00%) |
Mkt cap ! $57.67M |
Open | High | Low | Value | Volume |
4.0¢ | 4.3¢ | 4.0¢ | $48.01K | 1.160M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 1025000 | 3.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.2¢ | 461843 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 25000 | 0.039 |
1 | 1000000 | 0.038 |
1 | 500000 | 0.037 |
5 | 670534 | 0.036 |
5 | 985528 | 0.035 |
Price($) | Vol. | No. |
---|---|---|
0.042 | 461843 | 2 |
0.043 | 263169 | 2 |
0.044 | 13167 | 1 |
0.045 | 200000 | 1 |
0.046 | 69660 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online